← Research library

Method of treating systemic lupus erythematosus

Patent disclosure · 2000

What the patent describes
Same 61-patient lupus program as the 1999 publication; all Bemitil arms also received glucocorticoids.
Reported evidence
The patent describes four treatment groups using glucocorticoids with or without cyclophosphamide and Bemitil. It reports improvements in selected clinical and laboratory signs and anti-DNA antibodies in the Bemitil groups. This appears to describe the same research program as the 1999 paper.

Reported patent results

Reported findings

The patent reports lower anti-DNA antibodies and steroid changes in adjunctive Bemitil arms of the historical lupus program; unequal groups and follow-up prevent a causal efficacy estimate.

Same 61-patient lupus program as the 1999 publication; all Bemitil arms also received glucocorticoids.

Population or model Same 61-patient lupus program as the 1999 publication; all Bemitil arms also received glucocorticoids.

Results · Source passages checked 5 November 2026; see study record for access and limitations.
MeasureResultComparison, timing and statistics
Anti-DNA antibodiesReported within-group reductions in both Bemitil-containing armsp<0.001
Mean daily prednisolone, group 323.5 → 18.7 mg/day during observation
Mean daily prednisolone, group 114.7 → 29.0 mg/day during observation
Reported relapses / exacerbations11/30 without Bemitil at 6–12 months; 5/31 with Bemitil at 12–18 months

Historical treatment observations, not dosing advice. Unequal follow-up, baseline severity and treatment selection preclude a causal steroid-sparing claim or comparative relapse-risk calculation. Patent and paper are not independent replication.

Source for these results ↗ · Reviewed 2026-11-05

Patent claims and provenance

Use. Bemitil as an adjunct to glucocorticoids, with or without cyclophosphamide, in lupus. The patent and 1999 publication describe the same research program, not independent replications.

A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.

Publication
RU2157684C2 ↗ · 2000-10-20
Earliest priority / filing
1997-12-22 / 1997-12-22
Original applicant / assignee
Научно-исследовательский институт фармакологии Российской академии медицинских наук
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
20200796 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Agent for treatment of patients with systemic lupus erythematosis

Inventors: Т.А. Лисицына; А.Д. Дурнев; М.М. Иванова; С.Б. Середенин; В.А. Насонова.

RU2157684C2

Original patent PDF ↗

Patent collection and status interpretation →

Study limitations and source details

Study limitations

  • Patent reproduction; allocation concealment and blinding are not established. Treatment choice also reflected disease severity.
  • Numerous outcomes and unequal follow-up periods prevent a simple comparative relapse-rate interpretation.
  • Not an MS study or independent confirmation of the 1999 SLE report.

Related publications may describe some of the same participants or experiments.

Source details

Russian patent with English translation

The summary reflects the results reported in the cited source.

Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.

Sources checked

Citation

Patent / reported experimentsFull text available

T. A. Lisitsyna and colleagues. Method of treating systemic lupus erythematosus RU2157684C2. Filed 22 December 1997; published 20 October 2000

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards